About Nuvalent, Inc.
https://www.nuvalent.comNuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer.
CEO
James R. Porter
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 146
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Shares:17.99M
Value:$1.94B
FMR LLC
Shares:10.01M
Value:$1.08B
PARADIGM BIOCAPITAL ADVISORS LP
Shares:5.27M
Value:$568.26M
Summary
Showing Top 3 of 216
About Nuvalent, Inc.
https://www.nuvalent.comNuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $112.7M ▲ | $-122.44M ▼ | 0% | $-1.7 ▼ | $-122.31M ▼ |
| Q2-2025 | $0 | $104.57M ▲ | $-99.65M ▼ | 0% | $-1.39 ▼ | $-104.57M ▼ |
| Q1-2025 | $0 | $94.81M ▲ | $-84.58M ▼ | 0% | $-1.18 ▼ | $-94.81M ▼ |
| Q4-2024 | $0 | $86.3M ▲ | $-74.76M ▲ | 0% | $-1.05 ▲ | $-86.3M ▼ |
| Q3-2024 | $0 | $76.33M | $-84.34M | 0% | $-1.28 | $-76.33M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $943.1M ▼ | $979.91M ▼ | $134.51M ▲ | $845.4M ▼ |
| Q2-2025 | $1.01B ▼ | $1.04B ▼ | $100.8M ▲ | $939.74M ▼ |
| Q1-2025 | $1.07B ▼ | $1.11B ▼ | $94.75M ▲ | $1.01B ▼ |
| Q4-2024 | $1.12B ▼ | $1.14B ▼ | $71.96M ▲ | $1.07B ▼ |
| Q3-2024 | $1.17B | $1.19B | $67.73M | $1.12B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-122.44M ▼ | $-70.46M ▲ | $53.97M ▼ | $4.77M ▼ | $-11.72M ▼ | $-70.46M ▲ |
| Q2-2025 | $-99.65M ▼ | $-76.6M ▼ | $77.48M ▲ | $5.75M ▲ | $6.63M ▲ | $-76.6M ▼ |
| Q1-2025 | $-84.58M ▼ | $-54.82M ▲ | $25.42M ▲ | $4.55M ▼ | $-24.86M ▲ | $-54.82M ▲ |
| Q4-2024 | $-74.76M ▲ | $-62M ▼ | $-170.04M ▲ | $8.49M ▼ | $-223.55M ▼ | $-62M ▼ |
| Q3-2024 | $-84.34M | $-45.82M | $-212.91M | $550.27M | $291.54M | $-45.82M |
CEO
James R. Porter
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 146
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Shares:17.99M
Value:$1.94B
FMR LLC
Shares:10.01M
Value:$1.08B
PARADIGM BIOCAPITAL ADVISORS LP
Shares:5.27M
Value:$568.26M
Summary
Showing Top 3 of 216